U.S. Capital Wealth Advisors LLC Acquires 1,101 Shares of Cencora, Inc. (NYSE:COR)

U.S. Capital Wealth Advisors LLC lifted its holdings in shares of Cencora, Inc. (NYSE:COR - Free Report) by 15.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 8,249 shares of the company's stock after acquiring an additional 1,101 shares during the quarter. U.S. Capital Wealth Advisors LLC's holdings in Cencora were worth $1,853,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Insight Wealth Strategies LLC grew its position in Cencora by 124.6% during the 4th quarter. Insight Wealth Strategies LLC now owns 20,249 shares of the company's stock valued at $4,549,000 after purchasing an additional 11,232 shares during the last quarter. Cerity Partners LLC grew its position in Cencora by 10.1% in the 3rd quarter. Cerity Partners LLC now owns 39,457 shares of the company's stock worth $8,881,000 after purchasing an additional 3,610 shares during the period. Sylvest Advisors LLC purchased a new position in shares of Cencora in the 4th quarter worth $1,105,000. Thurston Springer Miller Herd & Titak Inc. lifted its holdings in Cencora by 71.1% in the fourth quarter. Thurston Springer Miller Herd & Titak Inc. now owns 7,048 shares of the company's stock valued at $1,583,000 after acquiring an additional 2,928 shares during the period. Finally, Portfolio Design Labs LLC bought a new position in Cencora in the 3rd quarter worth $1,404,000. 97.52% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Cencora news, EVP Silvana Battaglia sold 1,678 shares of the company's stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $228.72, for a total transaction of $383,792.16. Following the sale, the executive vice president now owns 20,329 shares in the company, valued at $4,649,648.88. This represents a 7.62 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Chairman Steven H. Collis sold 21,509 shares of the business's stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $242.16, for a total transaction of $5,208,619.44. Following the transaction, the chairman now directly owns 306,752 shares of the company's stock, valued at approximately $74,283,064.32. This trade represents a 6.55 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 73,187 shares of company stock worth $17,790,912. Corporate insiders own 10.80% of the company's stock.

Cencora Trading Up 0.6 %

NYSE:COR traded up $1.56 on Friday, reaching $247.69. The company's stock had a trading volume of 598,177 shares, compared to its average volume of 1,360,336. The stock has a 50 day moving average price of $239.08 and a 200 day moving average price of $236.51. Cencora, Inc. has a 12-month low of $214.77 and a 12-month high of $262.26. The company has a quick ratio of 0.53, a current ratio of 0.88 and a debt-to-equity ratio of 4.84. The firm has a market cap of $47.87 billion, a price-to-earnings ratio of 32.95, a price-to-earnings-growth ratio of 1.59 and a beta of 0.49.

Cencora (NYSE:COR - Get Free Report) last posted its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 EPS for the quarter, beating the consensus estimate of $3.50 by $0.23. Cencora had a net margin of 0.51% and a return on equity of 266.62%. On average, equities analysts anticipate that Cencora, Inc. will post 15.32 EPS for the current fiscal year.

Cencora Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 3rd. Shareholders of record on Friday, February 14th will be given a dividend of $0.55 per share. The ex-dividend date of this dividend is Friday, February 14th. This represents a $2.20 dividend on an annualized basis and a yield of 0.89%. Cencora's payout ratio is currently 29.29%.

Analyst Ratings Changes

A number of equities research analysts have issued reports on COR shares. Robert W. Baird increased their price target on Cencora from $287.00 to $292.00 and gave the stock an "outperform" rating in a research note on Thursday, November 7th. Mizuho started coverage on Cencora in a report on Wednesday, December 4th. They set an "outperform" rating and a $280.00 price objective on the stock. Barclays boosted their target price on Cencora from $263.00 to $290.00 and gave the company an "overweight" rating in a research report on Thursday, November 7th. UBS Group boosted their price objective on Cencora from $275.00 to $285.00 and gave the company a "buy" rating in a report on Thursday, November 7th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Cencora from $289.00 to $301.00 and gave the company an "overweight" rating in a research note on Friday, January 24th. Two equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $277.90.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.